Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 June 2021 | Story Dr Nitha Ramnath
Dr Charlene Marais, Prof Vladimir Azov and Prof Ulrich Hennecke

The Department of Chemistry at the University of the Free State (UFS) held a successful online International Symposium on Organic Chemistry on 15 June 2021. The symposium brought together scientists from several South African and foreign universities and created a virtual platform for a long-awaited discussion stalled by the COVID-19 pandemic. About 20 participants from universities in South Africa, Belgium, and Germany presented their lectures during the symposium. In addition, this symposium was directed at the postgraduate students in the Department of Chemistry at the UFS, allowing them to present their results to an international audience and to foster their engagement in scientific research.

For more than a year, the COVID-19 pandemic has prevented the common personal communication avenues for the researchers: face-to-face (F2F) conferences, symposia, and workshops. To bridge this gap, Prof Vladimir Azov and Dr Charlene Marais from the Department of Chemistry organised the online meeting for the researchers from the UFS and several other local and foreign universities, all working in the field of organic chemistry.

Online material from the International Symposium on Organic Chemistry is available at here

Collaborative project between the UFS and VUB towards the development of gel-based drug release systems

The symposium also served as a long-awaited inception meeting for the collaborative project between the Organic Chemistry group at the UFS and the Organic Chemistry (ORGC) group at the Vrije Universiteit Brussel (VUB). This project is jointly funded by the National Research Foundation (NRF) and FWO (Research Foundation – Flanders); it is aimed at the development of new peptide-based materials with properties controllable by precisely tuned interactions of unnatural amino acids included in the peptide sequence. Such peptides can, for example, be used as smart materials for precisely controllable drug release. The South African team members, directed by Prof Vladimir Azov, will specialise in the development of the new amino acid building blocks, whereas the VUB team, headed by Prof Ulrich Hennecke, will focus on peptide preparation and studies on their properties.

This kick-off meeting was initially planned as a F2F event in June 2020 but was delayed due to the COVID-19 travelling restrictions and finally migrated to a virtual space. This provided an opportunity to present the project proposals and to discuss the initial results in a much broader circle than would have been possible within the common F2F meeting framework.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept